Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001545672 XXXXXXXX LIVE 5 Common Stock, $0.0001 par value per share 12/23/2025 false 0001832038 00534A102 Invivyd, Inc. 209 Church Street New Haven CT 06510 Philip Chase (603) 643-7110 Adimab, LLC 7 Lucent Drive Lebanon NH 03766 0001545672 N Adimab, LLC OO N DE 20262170 20262170 20262170 N 7.3 OO Limited Liability Company Common Stock, $0.0001 par value per share Invivyd, Inc. 209 Church Street New Haven CT 06510 This Amendment No. 5 ("Amendment No. 5") amends and supplements the Schedule 13D originally filed by Adimab, LLC (the "Reporting Person") with the Securities and Exchange Commission (the "Commission") on March 30, 2022, as amended and supplemented by Amendment No. 1 thereto, filed with the Commission on April 26, 2022, Amendment No. 2 thereto, filed with the Commission on June 24, 2022, Amendment No. 3 thereto, filed with the Commission on January 22, 2024, and Amendment No. 4 thereto, filed with the Commission on November 19, 2025 (the "Original 13D," and together with this amendment, the "Schedule 13D"). Only those items that are hereby reported are amended; all other items reported in the Original 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 5 have the meanings ascribed to them in the Original 13D. This Amendment is being filed to report that the beneficial ownership of Common Stock by the Reporting Person has decreased by more than 1% as a result of the sales reported in Item 5. Item 5 of the Schedule 13D is hereby amended and restated as follows: (a) Amount beneficially owned: 20,262,170; Percent of Class: 7.3%. The above percentage is based on 277,122,834 shares of Common Stock outstanding, which includes 233,122,834 shares of Common Stock outstanding as of October 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and 44,000,000 shares of Common Stock issued on November 19, 2025, as reported in the Issuer's Current Report on Form 8-K filed on November 19, 2025. (b) The Reporting Person has sole voting and sole dispositive power with respect to all of the shares of Common Stock that it beneficially owns. On December 23, 2025, the Reporting Person sold 192,320 shares of Common Stock at a weighted average price of $3.0028 per share in a series of open market transactions. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.005 per share. The Reporting Person undertakes to provide to the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range. None Not applicable Adimab, LLC /s/ Philip Chase Philip Chase, Chief Executive Officer 12/29/2025